Gina Elhammady

Suggest Changes
Learn More
BACKGROUND The response to treatment and overall survival (OS) of patients with acute myeloid leukemia (AML) is variable, with a median ranging from 6 months to 11.5 years. TP53 is associated with(More)
  • 1